Oxygen utilization during and after isolated limb perfusion with rhTNFα and melphalan;O 2-utilisation wahrend und nach hyperthermer extremitatenperfusion mit rhTNFα und melphalan

Langenbecks Archiv fur Chirurgie

Volumn 382, Issue 3, 1997, Pages 128-133

  Haier, J ^a   Hohenberger, P ^a   Beck, K ^a   Schlag, P M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Isolated limb perfusion; Lactate; Oxygen utilization; Toxicity; Tumor necrosis factor (TNF) alpha

Indexed keywords

CARBON DIOXIDE; CYTOKINE; CYTOSTATIC AGENT; LACTIC ACID; MELPHALAN; OXYGEN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ALKYLATING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD GAS ANALYSIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; EXTRACORPOREAL CIRCULATION; HUMAN; HYPERTHERMIC THERAPY; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIMB PERFUSION; MELANOMA; OXYGEN CONSUMPTION; OXYGEN SATURATION; OXYGEN TISSUE LEVEL; REGIONAL PERFUSION; RHABDOMYOLYSIS; SOFT TISSUE SARCOMA; SWAN GANZ CATHETER; ADOLESCENT; BLOOD; DRUG EFFECT; FEMALE; LIMB; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; REPERFUSION INJURY; SARCOMA; SKIN TUMOR; SOFT TISSUE TUMOR; TREATMENT OUTCOME; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CARBON DIOXIDE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LACTIC ACID; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; OXYGEN; OXYGEN CONSUMPTION; REPERFUSION INJURY; SARCOMA; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030840798     PISSN: 00238236     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050040     Document Type: Article

References (24)

1. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, Geel AN van, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 224:756-765
2. Kettelhack C, Hohenberger P, Schlag PM (1996) Die isolierte Extremitätenperfusion mit Tumornekrosefaktor alpha und Melphalan beim malignen Melanom. Dtsch Med Wochschr 121:177-180
3. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60
4. Sorkin P, Abu Abid S, Lev D, Gutman M, Aderka D, Halpern P, Setton A, Kudlik N, Bar On J, Rudich V et al. (1995) Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 130:1079-1084
5. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL (1995) Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 13:264-273
6. Van der Zee J, Klaase JM, Van de Merve SA, Van der Berge AW, Van Slooten GW, Dongen JA van, Kroon BB (1991) Hyperthermia and melphalan in regional isolation perfusion. Strahlenther Onkol 167:341
7. Byrne DS, McKay AJ, Scott RN, Blackie R, Hughes J, Burnside G, MacKie RM (1990) Assessment of regional perfusion for melanoma by perioperative transcutaneous oxygen tension measurements. Reg Cancer Treat 3:88-89
8. Sprenger HJ, Markwardt J, Schlag PM (1994) Quantitative Leckkontrolle mit Radionukliden bei der isolierten Extremitä tenperfusion. Nucl Med 33:248-253
9. Wieberdink J, Bockhuizen C, Braat RP, Slooten EA van, Otthuis GAA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910
10. Schlag PM, Kettelhack C (1993) Weichteilsarkome: die hypertherme Extremitätenperfusion-Technik und Indikationen. Chirurg 64:455-460
11. Hohenberger P, Haier J, Schlag PM (1997) Rhabdomyolysis and renal function impairment after isolated limb perfusion - comparison between the effects of perfusion with rhTNFα and a triple-drug regimen. Eur J Cancer (in press)
12. Thompson JF, Lai DT, Ingvar C, Kam PC (1994) Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res [Suppl 1] 4:45-50
13. Sigurdsson GH, Nachbur B, Lejeune FJ (1993) Anesthesiologists' management of isolated limb perfusion with "high-dose" tumor necrosis factor alpha. Anesthesiology 79:1433-1437
14. Vrouenraets BC, Kroon BB, Klaase JM, Nieweg OE, Slooten GW van, Dongen JA van (1995) Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 5:425-431
15. Vrouenraets BC, Eggermont Am, Klaase JM, Geel BN van, Dongen JA van, Kroon BB (1994) Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 20:681-685
16. Sold M (1990) Der Stellenwert des Pulmonalarterienkatheters in Anaesthesie und Intensivmedizin. Anaesth Intensivmed 31:159-204
17. Hohenberger P, Bida B, Schlag PM (1996) Alterations of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or rhTNFα combined with melphalan. Strahlenther Onkol 172:14-18
18. Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 57:656-663
19. Smithies M, Bihari DJ (1993) Delivery dependent oxygen consumption: asking the wrong questions and not getting any answers. Crit Care Med 21:1622-1626
20. Boldt J, Hammermann H (1993) Der Pulmonalarterienkatheter. Anaesthesist 42:733-752
21. Goodman MN (1991) Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 260:727-730
22. Omlor G, Ecker KW, Gross G, Becker J, Hülsewede R (1991) Lactatanstieg nach hyperthermer Extremitätenperfusion - ein Maß für die intraoperative Muskelalteration. In: Waclawiczek HW (Hrsg) Das Maligne Melanom. Springer, Berlin Heidelberg New York, S 192-194
23. Eggimann P, Chiolero R, Chassot PG, Lienard D, Gerain J, Lejeune F (1995) Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 107:1074-1082
24. Fawcett WJ, Hill S, Sheldon J, Williams TR, Thomas JM, Riches P, Gore ME, Sont N (1993) Hemodynamic changes and circulating recombinant tumor necrosis factor-alpha concentrations in a patient undergoing isolated limb perfusion. Crit Care Med 21:796-800